| Document |
Document Title |
|
WO/2006/056443A2 |
Use of an activated solid phase and a peptide-conjugated anchoring part for solid phase peptide synthesis, wherein the anchoring part is coordinatively and reversibly attached to the activated solid phase.
|
|
WO/2006/054494A1 |
A compound represented by the following formula (1): [wherein R1 and R2 each independently represents hydroxy, provided that R1 and R2 may be bonded to each other to form methylenedioxy, etc.; X represents halogeno; and R3 represents a p...
|
|
WO/2006/050860A1 |
The invention relates to a method for producing perylene-3,4-dicarboxylic acid imides, which carry a sterically exacting substituent on the imide nitrogen atom, by reacting a perylene-3,4:9,10-tetracarboxylic acid dianhydride with a ster...
|
|
WO/2006/052710A1 |
4-Hydroxybenzomorphans containing carboxamide or thiocarboxamide at the 3-position are useful as analgesics, anti-diarrheal agents, anticonvulsants, antitussives and anti-addiction medications.
|
|
WO/2006/052722A1 |
The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/o...
|
|
WO/2006/051047A1 |
The invention relates to novel N-substituted imides and polymerizable compositions com¬ prising these N-substituted imides. The invention further relates to the use of N-substituted imides as polymerization initiators. The imides are co...
|
|
WO/2006/052430A2 |
Novel opiate intermediate compositions and methods of synthesis that include changing the substitution pattern on the aromatic ring of the pre-Grewe intermediate are provided. The intermediates are morphinane derivatives of formula (10) ...
|
|
WO/2006/050435A1 |
NLO chromophores of the form of Formula (I) and the acceptable salts, solvates and hydrates thereof, wherein Z, X1-4, &pgr 1-2, D and A have the definitions provided herein.
|
|
WO/2006/046778A1 |
A compound represented by the general formula (I): (wherein R1 is optionally substituted C1-8 alkyl, etc.; R2 is C1-6 alkyl and R3 is C1-6 alkyl, etc., provided that R2 and R3 may be bonded to each other to form an optionally substituted...
|
|
WO/2006/042481A1 |
Separation of the camphorsulfonic salts of the compounds of formula (I) and (II) by one or more crystallizations from a mixture of two solvents, both R(-)-10-camphorsulfonic acid and its salts with the compounds of formula (I) and (II) b...
|
|
WO/2006/040329A1 |
A novel class of compounds of the general formula (I), their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds modulate the a...
|
|
WO/2006/040177A1 |
The present invention relates to 6-amino(aza)indane compound of the formula (I) Wherein Ar is phenyl or an aromatic 5- or 6-membered C-bound heteroaromatic radical, wherein Ar may carry 1 radical Ra and wherein Ar may also carry I or 2 r...
|
|
WO/2006/035195A1 |
A process for preparing a compound of formula (A), (B) or (C): wherein P is H, CH3 or a hydroxyl protecting group; X is O, a protected ketone, OH, a protected hydroxyl group or H; Y is OH, a protected hydroxyl group or H; W is C(CH3)2OH,...
|
|
WO/2006/035967A1 |
The present invention encompasses novel substituted pyridine compounds of Formula (I), which act as MCH receptor antagonists. These compositions and pharmaceutical compositions thereof are useful in the prophylaxis or treatment of improv...
|
|
WO/2006/035303A1 |
This present invention generally relates to muscarinic receptor antagonists of Formula (I), which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated throu...
|
|
WO/2006/029167A2 |
The use of nalmefene and its analogs for treatment of conditions or diseases that are not mediated through opiate receptors is disclosed. Such condition and diseases include viral infections such as hepatitis B and C, organ damage, septi...
|
|
WO/2006/028239A1 |
A compound represented by, e.g., the formula (I): [Chemical formula 1] (I) [wherein X, Y, Z, and W each independently represents optionally substituted methine; A, B, and D each independently represents -C(O)-, etc.; Q represents methine...
|
|
WO/2006/028875A1 |
The present invention provides phenanthridine carbonyl compounds and compositions, particularly those that find use as ligands for the estrogen receptor. Representative compounds of the invention include those of formula 1.
|
|
WO/2006/027628A2 |
The present invention relates to the use of naphthalimide compounds of formula (I), wherein A, B, R1, R2, n and Ra are defined herein, and pharmaceutically acceptable salts thereof, for the treatment or prevention of infection by hepatit...
|
|
WO2005063239A9 |
The invention relates to amid compounds of general formula (I), wherein groups and residuals A, B, b, W, X, Y, Z, R
|
|
WO/2006/026531A1 |
An improved process for coating implantable medical devices utilizes a number of techniques for improving the stability of therapeutic agents contained within the coating. The stability of the therapeutic agents may be improved by creati...
|
|
WO/2006/026532A2 |
The invention relates to novel compounds and methods of treating diseases, disorders, and conditions associated with amyloidosis. Amyloidosis refers to a collection of diseases, disorders, and conditions associated with abnormal depositi...
|
|
WO/2006/023669A2 |
A process for the production of morphinans with higher purity and yield, when compared to the conventional process, is described. Specifically, the process may be used to prepare levorphanol, levorphanol tartrate, and levorphanol tartrat...
|
|
WO/2006/019955A2 |
Disclosed herein are antiviral compounds, such as anti-human cytomegalovirus antiviral compounds, pharmaceutical compositions and antiviral methods.
|
|
WO/2006/017542A1 |
Sulfonyl derivatives of structural formula I are selective inhibitors of the 11β-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesi...
|
|
WO/2006/009831A1 |
Synthetic methods are provided for production of compounds of the formula: (I) where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13 and R14 are as defined in the specification.
|
|
WO/2006/006071A1 |
A process of obtaining an enantiomerically enriched salt from a recamic mixture of a compound of formula (I), wherein R is hydrogen or benzyl.
|
|
WO/2006/001958A2 |
Compounds of the formulae (I) and (II): (wherein Q, X, E, G1, G2, R2, R3, R4, R5, R6 and Z are as defined herein) which are modulators of chemokine receptor activity and are useful in the prevention or treatment of certain inflammatory a...
|
|
WO/2006/002133A1 |
Compounds of Formula (I) and/or pharmaceutically acceptable salts, solvates or prodrugs thereof, or pharmaceutical compositions containing such compounds exhibit anti-inflammatory and immunomodulatory activity, and can be effective asCB2...
|
|
WO/2006/000562A1 |
The present invention relates to a process for the preparation of gabapentin and, more in particular, to a method of synthesis of 1,1-cyclohexane acetic acid monoamide, an intermediate used in the preparation of gabapentin, comprising th...
|
|
WO/2005/123089A2 |
Disclosed herein are carbonyl compounds of Formula (I) as described herein. Methods and compositions are disclosed for treating disease states including, but not limited to cancers, autoimmune diseases, tissue damage, central nervous sys...
|
|
WO/2005/121095A1 |
The present invention provides novel compounds of Formula I which are antagonists of the C5a receptor. Compounds of the present invention are useful for the treatment of various C5a-mediated diseases and disorders; accordingly the presen...
|
|
WO/2005/121073A1 |
The present invention relates to a benzamide derivative comprising a head, spacer and cap group wherein the spacer includes a benzene ring substituted with an additional spacer and wherein the additional spacer is an unsaturated group.
|
|
WO/2005/118581A1 |
The application relates to novel heterocyclic compounds of the general formula (I) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds as me...
|
|
WO/2005/119223A1 |
The present invention provides chemical compounds (compositions of matter) and method useful for determining pH and/or pH change in an environment. Specific compounds of the invention include at least five fused molecular rings.
|
|
WO/2005/117876A1 |
The present invention provides analogs and derivatives of thalidomide which inhibit cancer and angiogenesis. The present invention further provides compounds which disrupt microtubule polymerization. The present further provides methods ...
|
|
WO/2005/118540A2 |
The application relates to novel heterocyclic compounds of the general formula (I) (I*) in which R, R1, R2, X, Y, Z and n have the meanings defined in the description, to a process for their preparation and to the use of these compounds ...
|
|
WO/2005/118543A1 |
A compound represented by the general formula (I): [wherein A represents optionally substituted amino or a group represented by the formula (II) (wherein ring A1 represents an optionally substituted nitrogenous heterocyclic group); D rep...
|
|
WO/2005/115361A2 |
Disclosed herein are bicycloaryl compounds of Formula (I) that selectively modulate nuclear receptors, preferably the androgen receptor, or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof, and methods of treating dis...
|
|
WO2005058298B1 |
The present invention provides FK228 analogs and methods of making and using the same. Such analogs are potent inhibitors of histone deacetylase and, in certain embodiments, are capable of specifically targeting cancerous cells and tissu...
|
|
WO/2005/112945A2 |
The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among man...
|
|
WO/2005/110992A1 |
The present invention relates to inhibitors of 11-ß hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the ...
|
|
WO/2005/107763A2 |
A novel group of apomorphine derivatives are provided that are well suited as radioimaging agents upon incorporation of radionuclides. Through reaction of D ring sites, the less reactive sites of the apomorphine A ring is modified in way...
|
|
WO/2005/108370A1 |
It is intended to provide benzene compounds represented by the following formulae and analogs thereof which exert an ACC activity inhibitory effect and are efficacious in treating hyperlipemia, fatty liver, impaired glucose tolerance, di...
|
|
WO/2005/105753A2 |
Novel substituted naphthalimide derivatives of formula (I) and (II), pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such ...
|
|
WO/2005/105752A1 |
The present invention relates to compounds of the general formula (IV) and (II) and salts and physiologically functional derivatives thereof, (IV), (II) wherein X is C-R 8 or N; and Z is independently one of the following groups: (Ia), (...
|
|
WO/2005/103009A1 |
The present invention concerns the use of compound of formula (I) or (II) and their pharmaceutically acceptable salts in the preparation of a pharmaceutical composition useful namely in an anti-malarial prophylactic or curative treatment...
|
|
WO/2005/103008A1 |
The present invention concerns the use of compound of Formula (I), or Formula (II), and their pharmaceutically acceptable salts in the preparation of a pharmaceutical composition useful namely in an anti-malarial prophylactic or curative...
|
|
WO/2005/102250A1 |
The invention relates to a cosmetic or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one type of polymer containing at least one type of novel monomer compound exhibiting optical properties. Said...
|
|
WO/2005/099707A1 |
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen defic...
|
